ClinicalTrials.gg
CompletedNCT01415895Updated Apr 14, 2021

Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain

A Phase 2 interventional study of Naltrexone and Clonidine Combination and placebo in Back Pain, Lower Back Pain and Cervical Pain, sponsored by Annette C. Toledano MD. Completed at 1 site in United States. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-04-14.

Primary conditionLow Back PainRegistry: Back PainReclassifiedWhy we changed it
Registry
Back Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Low Back Pain
Why
  1. The study's listed conditions name Low Back Pain, a narrower term within Back Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Annette C. Toledano MD · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 711 studies in Low Back Pain with a site in United States — 99 open to participants now, 125 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
313th of 623
78 · median 79
Started
2011
with 35 others
Phase 2
59 of 711
7 open now
Registered
187th of 711
by date

Among the 711 studies in Low Back Pain with a site in United States, this one is the 313th largest by enrollment of the 623 interventional ones that give a count, is one of 36 that started in 2011, is one of 59 in phase 2, and was the 187th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

99 of the 711 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 92 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 711 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

The study includes back pain of the cervical, thoracic, and the lumbar regions.

03

Conditions studied

  • Back Pain
  • Lower Back Pain
  • Cervical Pain

Browse trials for

Keywords

  • back pain
  • cervical pain
  • neuropathic pain
  • radicular pain
04

In context

Low Back Pain Reclassified

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

This study's enrollment of 78 is above the median of 60 across 2,364 interventional studies indexed under Low Back Pain.

Browse Low Back Pain studies →

Lead sponsor

This is the only study on the registry with Annette C. Toledano MD as lead sponsor.

Compared within Low Back Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Back Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subject has chronic back pain for > 3 months in the lumbar, thoracic or cervical regions.

The average pain intensity scale during the screening week is 4/10 - 8/10 (On an 11-point Numeric Pain Intensity Scale with 0 = no pain and 10 = worst pain imaginable).

The subject has not taken Opioid medications 7 days prior to initiation of study drug.

The subject has a heart rate of 60bpm or above and/or systolic blood pressure 90 or above.

The subject is willing to refrain from using NSAIDS, Acetaminophen or muscle relaxants, unless for rescue, for the duration of the study The subject is willing to refrain from using Opioid medications and excessive alcohol for the duration of the study.

The subject is able to read, understand and follow the study instructions, including completion of questionnaires at home.

The subject must sign an document indicating willingness to participate.

If the subject is a female, she must be , not currently pregnant or nursing. A female of child bearing potential should be using a reliable method during the course of the study.

Exclusion criteria

Exclusion Criteria:

The subject has a positive urine drug screen. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.

The subject has any significant deviations from normal in physical examination, (ECG), Echocardiogram or clinical laboratory tests, as evaluated by the investigator.

The subject has a history of an allergic reaction to the components of the study drug.

The subject has acute back or cervical pain. The subject has muscular back or cervical pain. The subject has back or cervical pain other than chronic Radicular pain.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    ATNC05 - a study drug capsule

    Naltrexone and Clonidine Combination (ATNC05)

    Drug: Naltrexone and Clonidine Combination

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

  • DrugNaltrexone and Clonidine Combination

    Drug pages: Naltrexone · Clonidine

    subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.

    Also known as: ATNC05

  • Drugplacebo

    subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.

07

What researchers measure

Primary outcomes

  1. Change from Baseline in Brief Pain Inventory 24-hour Pain Scores for average pain (Question #5)

    The Brief Pain Inventory is a self-reported medical questionnaire used to measure pain over the past 24-hours - worst pain (Question 3), least pain (Question 4), average pain (Question 5), right now pain (Question 6) and at night pain (Question 7). The score ranges from 0 to 10 (0 - no pain) (10 - intolerable pain).

    Time frame: baseline to week 3

Secondary outcomes

  1. Change from Baseline in Brief Pain Inventory 24-hour assessment of interference in function (Questions 9a - 9i).

    BPI Interference; questions 9a - 9i - measures a self-reported assessment of the interference in function because of pain in past 24 hours in general activity, mood, walking ability, normal work, relationship with other people, sleep quality, enjoyment of life, standing ability and sitting ability. Interference scores: 0 (does not interfere) to 10 (completely interferes).

    Time frame: baseline to week 1, week 2 and week 3

  2. Change From Baseline in Brief Pain Inventory 24-hour subject's Global Impression of Improvement (Question 8)

    The Brief Pain Inventory question 8 measures the subject's perception of how much relief he has received at the time of assessment compared with before the start of the study drug. The score is measured in percentage 0% (no relief) to100% (complete relief).

    Time frame: baseline to week 1, week 2 and week 3

  3. Change From Baseline in the subject's Global Assessment of Treatment Satisfaction today

    A self-reported scale that measures Treatment Satisfaction today in (0-10, 0 - none, 10 - most satisfied)

    Time frame: baseline to week 1, week 2 and week 3

  4. Change from Baseline in the subject's perception of Ability to Tolerate the study drug and the severity of side effects today.

    A self-reported scale that measures the ability to tolerate the study drug and the severity of side effects today in (0-10, 0 - No side effects, 10 - intolerable side effects)

    Time frame: baseline to week 1, week 2 and week 3

  5. Change From Baseline in Oswestry Disability Index and Neck Disability composite scores(ODI), to Week 1, Week 2, and Week 3

    The Oswestry Low Back Pain Disability Questionnaire (Oswestry Disability Index) and Neck Disability composite assesses pain-related disability in persons with low back pain (LBP) and neck pain. The score is recorded in percentage of disability.

    Time frame: baseline to week 1, week 2 and week 3

  6. Change From Baseline in Roland Morris Disability Questionnaire composite scores(ODI), to Week 1, Week 2, and Week 3

    The Roland Morris Disability Questionnaire consists of 24 statements and the subject is instructed to put a mark next to each appropriate statement. The total score ranges from 0 (no disability) to 24 (severe disability).

    Time frame: baseline to week 1, week 2 and week 3

  7. Change From Baseline in Vital Signs - systolic blood pressure, diastolic blood pressure, pulse rate and body mass index to Week 1, Week 2, and Week 3.

    Time frame: baseline to week 1, week 2 and week 3

  8. Change from Baseline to week 3 in Laboratory Assessments - Alkaline Phosphatase, Alanine Transaminase - ALT (SGPT), Aspartate transaminase - AST(SGOT), Bilirubin, Total, Serum Creatinine, Blood Urea Nitrogen, Serum Chloride, Potassium, HCO3

    Time frame: baseline to week 1, week 2 and week 3

  9. Change from Baseline in the investigator's Clinical Global Impression - Severity scale (CGI-S) to Week 1, Week 2, week 3 .

    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the investigator to rate the severity of the subject's back pain at the time of assessment, relative to the investigator's past experience. Considering total clinical experience, the subject is assessed on severity of back pain at the time of rating 1, normal; 2, borderline; 3, mild; 4, moderate; 5, marked; 6, severe; or 7, extreme.

    Time frame: baseline to week 1, week 2 and week 3

  10. Change from Baseline in The investigator's Clinical Global Impression - Improvement scale (CGI-I) to Week 1, Week 2, week 3

    The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale, the investigator will rate how much the patient's back pain has improved or worsened relative to a baseline state at the beginning of the study and rate as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

    Time frame: baseline to week 1, week 2 and week 3

  11. Change from Baseline in the subject's answer to the question, "Are you better off today then the time before starting the study drug?, yes/no, by what percentage?

    Answer, yes/no and by 0%-100% (0%-not at all better, 100% - very much better off

    Time frame: baseline to week 1, week 2 and week 3

  12. Change From Baseline in the subject's answer to the question " Have you been more / less active in the past 24 hrs, comparing to the period before initiating the study drug, please rate in %.

    The subjects answer, one of the following choices, - 150%, -100%, -50%, - 25%, 0% - same activity level, +25%, +50%, +100%, +150%

    Time frame: baseline to week 1, week 2 and week 3

  13. Subject's response to the question, "Have you responded to the treatment?"

    Subject's answer yes/no.

    Time frame: baseline to week 1, week 2 and week 3

  14. Subject's Global Assessment of Disease Activity Improved / No Change

    The Subject answer either Improved or No Change.

    Time frame: baseline to week 1, week 2 and week 3

  15. Subject's Global Evaluation of Study Medication.

    The subject chooses, 1 - Excellent, 2 - Very Good, 3 - Good, 4 - Fair, 5 - Poor

    Time frame: baseline to week 1, week 2 and week 3

  16. The Subject's Satisfaction with Pain Relief, 0 - 10.

    The subject answers on a scale of 0-10, (0 - not satisfied, 10 - very satisfied).

    Time frame: baseline to week 1, week 2 and week 3

  17. The Subject's Satisfaction with Moving, Standing, Walking and Bending Ability Scale, 0-10.

    The subjects answers on a scale of 0-10, (0 - not satisfied, 10 - very satisfied)

    Time frame: baseline to week 1, week 2 and week 3.

  18. Change from Baseline in Brief Pain Inventory 24-hour Pain Scores for worst pain, least pain, right now pain and night pain (Questions 3,4,6 & 7)

    The Brief Pain Inventory is a self-reported medical questionnaire used to measure pain over the past 24-hours - worst pain (Question 3), least pain (Question 4), average pain (Question 5), right now pain (Question 6) and at night pain (Question 7). The score ranges from 0 to 10 (0 - no pain) (10 - intolerable pain).

    Time frame: baseline to week 1, week 2 and week 3

08

Study locations

1 site
  • Annette C. Toledano MD
    North Miami, Florida 33181, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2011
First posted
Aug 12, 2011
Start
Jul 2011
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Last update
Apr 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01415895
Lead sponsor
Annette C. Toledano MD
Responsible party
Annette C. Toledano MD (Sponsor/Investigator, Allodynic Therapeutics, Inc) — Sponsor-investigator
First posted
Aug 12, 2011
Start date
Jul 2011
Primary completion
Feb 2013
Completion
Feb 2013
Last update
Apr 14, 2021

Study contacts

Annette C Toledano, MD
principal investigator · Allodynic Therapeutics, Inc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naltrexone · Clonidine

Start the discussion